Patients up next for drug price input
All the makers of the 10 drugs subject to the inaugural Medicare drug price negotiations have opted into the talks with CMS.
Source: politico.com
📰 Genentech News
Page 95 - Genentech News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Genentech. Real-time updates on events, politics, business and more.
Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strength of Long-term Outcomes in MS and NMOSD
–– Late-breaking results from Phase III trial of Ocrevus subcutaneous injection and Phase II trial of BTK inhibitor fenebrutinib in multiple sclerosis will be presented –– 10-year Ocrevus...
United States South San Francisco Levi Garraway Roche Group Research In Multiple Sclerosis Global Product Development
Source: marketscreener.com
AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma
AbbVie (NYSE: ABBV) today announced data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax (VENCLEXTA®/ VENCLYXTO®) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received two or more prior treatments. Data did not ...
United Kingdom Rheinland Pfalz Mariana Cota Stirner Venclyxto Sm Exchange Commission International Myeloma Society Annual Meeting
Source: pharmiweb.com
Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strengt
–– Late-breaking results from Phase III trial of Ocrevus (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitor fenebrutinib in multiple sclerosis (MS) will be presented–– 10-year Ocrevus efficacy and safety data show significant benefit in slowing long-term disability progression and consistent lo...
Source: pharmiweb.com
Sonoma Biotherapeutics Appoints Joseph R. Arron, M.D., Ph.D., as Chief Scientific Officer and Mark D. Eisner, M.D., MPH, as Chief Medical Officer
Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced the appointments of Joseph R. Arron, M.D., Ph.D., as Chief...
Stanford University United States San Francisco South San Francisco Sonoma Biotherapeutics Fred Ramsdell
Source: lelezard.com
KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING
SYDNEY, Sept. 29, 2023 /PRNewswire/ -- Kazia Therapeutics Limited , an oncology-focused drug development company, is pleased to announce that data from an ongoing Phase II study of paxalisib, an...
Source: marketscreener.com
Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine -September 28, 2023 at 12:25 pm EDT
COMIRNATY Omicron XBB.1.5-adapted monovalent COVID-19 vaccine is now authorized in Canada for individuals 6 months of age and olderNew Omicron XBB.1.5-adapted COVID-19 vaccine is administered as a...
Source: marketscreener.com
AnHeart Therapeutics Appoints Charlotte Arnold as Chief Corporate Affairs Officer
NEW YORK--(BUSINESS WIRE)--Sep 28, 2023--
Source: eagletribune.com
Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine -September 28, 2023 at 12:24 pm EDT
COMIRNATY Omicron XBB.1.5-adapted monovalent COVID-19 vaccine is now authorized in Canada for individuals 6 months of age and olderNew Omicron XBB.1.5-adapted COVID-19 vaccine is administered as a...
United Kingdom United States Ugur Sahin Fosun Pharma Pfizer Canada Corporate Affairs Globenewswire Inc
Source: marketscreener.com
Pfizer and BioNTech Receive Health Canada Authorization for
COMIRNATY Omicron XBB.1.5-adapted monovalent COVID-19 vaccine is now authorized in Canada for individuals 6 months of age and olderNew Omicron...
Source: globenewswire.com